Given CIP2A’s activation of oncogenic and metabolic pathways (e.g., c-Myc, AKT, PKM2), E-cadherin expression in this setting may represent phenotypic adaptation rather than tumor suppression. The gene discussed is CIP2A; the disease is neoplasm.